Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 150,000 Shares

Posted by Brenda Bartman on Aug 8th, 2023

Verona Pharma plc (NASDAQ:VRNA – Get Free Report) CEO David Zaccardelli sold 150,000 shares of Verona Pharma stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $2.50, for a total transaction of $375,000.00. Following the transaction, the chief executive officer now directly owns 16,440,416 shares in the company, valued at approximately $41,101,040. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

David Zaccardelli also recently made the following trade(s):

On Monday, August 7th, David Zaccardelli sold 8,616 shares of Verona Pharma stock. The shares were sold at an average price of $2.47, for a total transaction of $21,281.52.
On Wednesday, August 2nd, David Zaccardelli sold 73,704 shares of Verona Pharma stock. The shares were sold at an average price of $2.59, for a total transaction of $190,893.36.

Verona Pharma Stock Down 4.5 %

Shares of NASDAQ VRNA traded down $0.89 during mid-day trading on Monday, hitting $19.04. The company had a trading volume of 319,228 shares, compared to its average volume of 511,897. Verona Pharma plc has a one year low of $6.54 and a one year high of $26.44. The company has a market capitalization of $12.10 billion, a PE ratio of -26.57 and a beta of 0.18. The company has a current ratio of 26.29, a quick ratio of 26.29 and a debt-to-equity ratio of 0.07. The firm has a 50-day simple moving average of $20.99 and a two-hundred day simple moving average of $21.12.

Verona Pharma (NASDAQ:VRNA – Get Free Report) last posted its quarterly earnings results on Tuesday, May 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). On average, equities analysts expect that Verona Pharma plc will post -1 EPS for the current year.

Analyst Ratings Changes

VRNA has been the topic of several recent analyst reports. 500.com reiterated a “reiterates” rating on shares of Verona Pharma in a report on Wednesday, June 28th. Wedbush reissued an “outperform” rating and set a $30.00 price objective on shares of Verona Pharma in a research report on Friday. HC Wainwright reissued a “buy” rating and set a $32.00 price objective on shares of Verona Pharma in a research report on Friday. Finally, Truist Financial increased their price objective on shares of Verona Pharma from $28.00 to $32.00 in a research report on Wednesday, June 7th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Verona Pharma has a consensus rating of “Buy” and a consensus price target of $30.50.

Check Out Our Latest Stock Analysis on VRNA

Hedge Funds Weigh In On Verona Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tucker Asset Management LLC bought a new stake in shares of Verona Pharma in the 1st quarter valued at about $49,000. UBS Group AG boosted its stake in shares of Verona Pharma by 435.9% during the 4th quarter. UBS Group AG now owns 4,169 shares of the company’s stock worth $109,000 after acquiring an additional 3,391 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Verona Pharma by 520.2% during the 1st quarter. Tower Research Capital LLC TRC now owns 4,534 shares of the company’s stock worth $91,000 after acquiring an additional 3,803 shares during the period. SG Americas Securities LLC bought a new position in shares of Verona Pharma during the 1st quarter worth approximately $105,000. Finally, New York State Common Retirement Fund bought a new position in shares of Verona Pharma in the first quarter valued at about $143,000. 77.97% of the stock is owned by institutional investors.

Verona Pharma Company Profile

(Get Free Report)

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.